Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects undergoing outpatient surgeries (laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy) under general anesthesia requiring rocuronium-induced neuromuscular blockade~2. Male or female patient 18 years and older~3. Able to consent~4. American Society of Anesthesiologist (ASA) physical status of I, II, or III~Exclusion Criteria:~1. Participating in another interventional study drug within 30 days prior to their recruitment~2. Special population (Pregnant, Inmate, Breastfeeding)~3. History of allergy to sugammadex or rocuronium~4. Any medication known to interfere with NMBA or sugammadex~5. Presence of any clinical condition as determined by the investigator that exclude the patient from the trial such as COPD, CKD, and neuromuscular or neurodegenerative diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sugammadex (Type: ACTIVE_COMPARATOR): * If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~* If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~* When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg
- Neostigmine (Type: ACTIVE_COMPARATOR): 50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.

Based on this trial design, predict the completion outcome and termination type (if applicable).